Participant flow

Rituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System Lymphoma · Source last updated 2023-07-03

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   rituximab cytarabine dexamethasone leucovorin calcium methotrexate procarbazine hydrochloride vincristine sulfate

   id

   FG000

   title

   Rituximab + Standard Chemotherapy

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Ineligible

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         26

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         25

      type

      Eligible

   3. achievements

      1. group Id

         FG000

         num Subjects

         25

      type

      Treated

   4. achievements

      1. group Id

         FG000

         num Subjects

         25

      type

      COMPLETED

   5. achievements

      1. group Id

         FG000

         num Subjects

         1

      type

      NOT COMPLETED

   title

   Overall Study

recruitment Details

Participants were recruited from ECOG-ACRIN member institutions starting 12/21/2006 and accrued its first patient on 08/23/2007. The study was suspended 2/24/2010 for interim analysis. After the interim analysis, it was determined that the goals of the study had been met and the study was closed on 4/12/2013.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice